The DCA treatment groups showed significantly lower CD133-positivity and sphere-forming ratio than the control cells (Fig 5A and 5B) suggesting that DCA suppressed cancer stem-like phenotypes in rMSLCs in vitro and consistent with previous findings for glioma and breast CSLCs [22, 53]. The gene discussed is PROM1; the disease is glioma.